GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (LTS:0OCQ) » Definitions » Policy Acquisition Expense

Transgene (LTS:0OCQ) Policy Acquisition Expense


View and export this data going back to 2008. Start your Free Trial

What is Transgene Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Transgene Business Description

Industry
Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.